Overview

* Exelixis Q2 2025 revenue misses analyst expectations, adjusted EPS beats, per LSEG data

* Net product revenues rose due to higher sales volume of cabozantinib franchise

* Co reports positive results from STELLAR-303 trial in colorectal cancer

Outlook

* Exelixis ( EXEL ) maintains 2025 revenue guidance at $2.25 bln - $2.35 bln

* Company expects 2025 net product revenues of $2.05 bln - $2.15 bln

* Exelixis ( EXEL ) anticipates 2025 R&D expenses of $925 mln - $975 mln

* Company plans to announce new zanzalintinib trials soon

Result Drivers

* CABOMETYX LAUNCH - Successful U.S. launch for advanced neuroendocrine tumors, capturing leading share of new patient starts

* HIGHER SALES VOLUME - Increase in net product revenues driven by higher sales volume of cabozantinib franchise

* STELLAR-303 RESULTS - Positive topline results in colorectal cancer, plans to seek regulatory approval

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q2 Miss $568.30 $574.50

Revenue mln mln (19

Analysts

)

Q2 Beat $0.75 $0.56

Adjusted (16

EPS Analysts

)

Q2 Beat $212.60 $158.30

Adjusted mln mln (15

Net Analysts

Income )

Q2 Net $184.80

Income mln

Analyst Coverage

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 11 "strong buy" or "buy", 9 "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the biotechnology & medical research peer group is "buy"

* Wall Street's median 12-month price target for Exelixis Inc ( EXEL ) is $46.00, about 0.9% above its July 25 closing price of $45.60

* The stock recently traded at 18 times the next 12-month earnings vs. a P/E of 17 three months ago

Press Release:

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)